Table 2. Distribution of positive expression of EpCAM, CA9 and CD147 in the RCC patient cohort.
I | II | III | IV | Total | |
---|---|---|---|---|---|
CA9+ | 27/29 93.1% | 18/19 94.7% | 13/16 81.3% | 4/6 66.7% | 62/70 88.6% |
CD147+ | 22/29 75.9% | 15/19 79.0% | 15/16 93.8% | 6/6 100% | 58/70 82.9% |
EpCAM+ | 8/29 27.6% | 3/19 15.8% | 1/16 6.3% | 1/6 16.7% | 13/70 18.6% |
CA9+ and/or CD147+ | 28/29 96.5% | 19/19 100% | 15/16 93.8% | 6/6 100% | 68/70 97.1% |
CA9+ and/or CD147+ in EpCAM+ group | 8/8 100% | 3/3 100% | 1/1 100% | 1/1 100% | 13/13 100% |
CA9+ and/or CD147+ in EpCAM− group | 20/21 95.2% | 16/16 100% | 14/15 93.3% | 5/5 100% | 55/57 96.4% |